BRAIN Biotech AG

BRAIN Biotech AG takes next step to optimize group structure

Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams

Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives

BRAIN Biotech AG: Issuance of EUR 5 million convertible bond with exclusion of subscription rights

3M FY 23/24:  BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24

BRAIN Biotech AG: Bekanntmachung der Einberufung zur Hauptversammlung am 12.03.2024 in Zwingenberg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Annual Report 2022/23: BRAIN Biotech AG successfully executes growth strategy

Akribion Genomics receives the Hessian Founder Award for its innovative approach to a new cancer therapy

BRAIN Biotech AG: BRAIN Biotech AG´s Akribion Genomics team wins first prize at the “BioRiver Boost!” startup competition

BRAIN Biotech AG: BRAIN Biotech AG’s Akribion Genomics technology receives patent approval for its groundbreaking nuclease G-dase E®

BRAIN Biotech AG: Scientist from BRAIN Biotech AG receives VAAM Innovation Award for the discovery of a novel CRISPR nuclease family

BRAIN Biotech AG reports solid 9M numbers despite ongoing high R&D investments and more challenging economic conditions

BRAIN Biotech AG´s Akribion Genomics team successfully competes in Science4Life Venture Cup competition

Anniversary of BRAIN Biotech AG: 30 years for a bio-based future

BRAIN Biotech AG stays on solid growth path with H1 results and accelerates One-BioProducts strategy

BRAIN Biotech AG gains full ownership of Biocatalysts Ltd and accelerates execution of its One-BioProducts Strategy

BRAIN Biotech AG: Dr. Michael Majerus, buy

Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG

Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion

BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting

BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment

BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères

BRAIN Biotech AG: Bekanntmachung der Einberufung zur Hauptversammlung am 08.03.2023 in Offenbach am Main mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

BRAIN Biotech AG reports record figures in fiscal year 2021/22 − despite challenging geopolitical environment

BRAIN Biotech AG: BRAIN Group’s Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform